Bestselling asthma drugs from Novartis and respiratory behemoth GlaxoSmithKline are also showing more adverse events in post-marketing safety data than competing products from Merck, according to a new report, potentially presenting issues further down the line as companies duke it out for market share.
Merck, angling to compete with dominant hepatitis C treatments from Gilead Sciences and AbbVie, posted positive results for its in-development combos as it works to demonstrate their ability to cure more patients faster.
An independent data-monitoring panel recommended that Merck & Co. continue studying its cholesterol-fighting CETP inhibitor, anacetrapib.
Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics of the antibiotic Cubicin, the drug that was key to its $9.5 billion buyout of Cubist. Next up may be an appeal to the U.S. Supreme Court.
Merck announced Nov. 12 that it will acquire Harrisvaccines, a private Iowa company that made news in October when the USDA appointed it to manufacture avian influenza vaccines for an emergency stockpile.
Merck, the last Big Pharma standing in CETP inhibition, is pressing forward with a huge cardiovascular trial after getting the green light from its independent advisers, stepping over the scattered failures of similar projects in hopes of hitting upon a blockbuster.
For years, Merck and GlaxoSmithKline have battled safety worries and other stigmas with their HPV vaccines. But this week, the companies received a piece of positive news from the European Medicines Agency, which reported that a committee found no link between the shots and two rare conditions it had been studying.
Big Pharma has been dealing with government pushback over drug pricing. Now, Eli Lilly and Merck are joining Valeant in the hot seat as the U.S. Department of Justice probes the companies over how they report prices to government-funded drug programs.
Big Pharma has been getting it from all sides lately over drug pricing, with companies such as Valeant taking most of the heat as lawmakers, presidential candidates and the public weigh in on the issue. But now Eli Lilly and Merck are joining Valeant in the hot seat as the U.S. Department of Justice probes the companies over how they report prices to government-funded drug programs.
Zac, Jessica, Jana and Julie are "Beyond Tired." That's the name of the new awareness campaign from Merck & Co. and the National Sleep Foundation, featuring four average Americans and their insomnia experiences as a way to promote and discuss sleep health.